Medtech LENSAR Q2 revenue rises 10% but misses analyst expectations

LENSAR

07/08/2025 12:10

Overview

LENSAR Q2 revenue rises 10% yr/yr to $13.9 mln, missing analyst expectations

Company reports net loss of $1.8 mln, improved from $9.0 mln loss in Q2 2024

Co's merger with Alcon approved by stockholders, expected to close by year-end

Result Drivers

ALLY SYSTEMS GROWTH - Installed base of ALLY Systems grew 107% compared to 2Q 2024, driving revenue increase

PROCEDURE VOLUME - Worldwide procedure volumes increased 23% over 2Q 2024, contributing to revenue growth

MERGER COSTS - Selling, general and administrative expenses rose due to $4.2 mln in acquisition-related costs for Alcon merger

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$13.90 mln
$16.60 mln (2 Analysts)
Q2 Net Income
-$1.80 mln
Q2 EBITDA
-$900,000


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for LENSAR Inc is $15.00, about 13.1% above its August 6 closing price of $13.03

Press Release: ID:nGNXb4F51r

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)